Article

Novartis to market antibody fragment

Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
Related Content
A case of retinal detachment in tertiary syphilis
April 5th 2025

A case of retinal detachment in tertiary syphilis

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Novel radiosurgical platform to treat a case of uveal melanoma
April 4th 2025

Novel radiosurgical platform to treat a case of uveal melanoma

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap
April 3rd 2025

FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap

Methylphenidate may impact corneal cells in children with ADHD
April 3rd 2025

Methylphenidate may impact corneal cells in children with ADHD

© 2025 MJH Life Sciences

All rights reserved.